Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


France’s Gemme Unveils Three-Point Plan To Bolster Biosimilars

As Biosimilar Penetration Falls Short Of Government’s ‘Ambitious’ Target

Executive Summary

Fresh impetus is needed to help biosimilars achieve their full potential in France, according to off-patent industry association Gemme. The organization has unveiled a three-point plan to bolster the sector that includes proposals to allow pharmacists to substitute biosimilars for brand prescriptions under certain circumstances.

You may also be interested in...

Stakeholders Surprised As French Biosimilar Substitution Changes Tack

The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.

French Body Favors Pharmacy Substitution For Biosimilars

French off-patent association Gemme has made a bold show of support for pharmacy-level biosimilar substitution in a position statement published by the industry body. However, the proposals run against the views of broader European industry association Medicines for Europe and come against the backdrop of recently-adopted French legislation that ensures doctors will be involved in biologic substitution.

France sets 80% biosimilar goal

Agoal of 80% biosimilar penetration within their individual markets by 2022 has been set by France’s government, as part of a broader healthcare strategy set out by the health ministry for the next five years. This will be achieved by promoting biosimilars “which present the same efficacy, the same quality and the same safety as the biological reference product”, according to the proposals. Local medicines agency ANSM recently introduced 11 ‘similar biologic groups’ designating equivalence categories for biosimilars, alongside guidance that advises prescribing biosimilars at any point during a course of treatment and favours lowerpriced alternatives (Generics bulletin, 10 November 2017, page 11).


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts